$28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter

Brokerages expect FibroGen (NASDAQ:FGEN) to announce sales of $28.23 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for FibroGen’s earnings, with the lowest sales estimate coming in at $27.40 million and the highest estimate coming in at $29.00 million. FibroGen posted sales of $26.89 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 5%. The firm is scheduled to announce its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that FibroGen will report full year sales of $192.38 million for the current financial year, with estimates ranging from $127.00 million to $225.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $358.32 million per share, with estimates ranging from $281.00 million to $464.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow FibroGen.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.01. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. The firm had revenue of $42.51 million for the quarter, compared to analyst estimates of $45.37 million.



Several equities research analysts recently weighed in on FGEN shares. TheStreet raised shares of FibroGen from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Mizuho reaffirmed a “hold” rating and set a $61.00 target price on shares of FibroGen in a research note on Thursday, March 29th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. FibroGen presently has a consensus rating of “Hold” and an average target price of $66.67.

In other FibroGen news, Director Jorma Routti sold 6,000 shares of the stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $46.59, for a total value of $279,540.00. Following the sale, the director now directly owns 133,840 shares of the company’s stock, valued at approximately $6,235,605.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Roberto Pedro Rosenkranz sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $52.34, for a total transaction of $52,340.00. Following the completion of the sale, the director now directly owns 24,000 shares in the company, valued at $1,256,160. The disclosure for this sale can be found here. Over the last three months, insiders sold 433,799 shares of company stock worth $23,216,568. Insiders own 13.60% of the company’s stock.

Large investors have recently made changes to their positions in the business. Bank of Montreal Can increased its position in shares of FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. increased its position in shares of FibroGen by 95.0% in the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of FibroGen by 41.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 1,147 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of FibroGen by 112.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,336 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of FibroGen in the 4th quarter valued at approximately $255,000. 61.39% of the stock is currently owned by institutional investors.

Shares of FGEN stock opened at $48.05 on Friday. The company has a current ratio of 9.70, a quick ratio of 9.70 and a debt-to-equity ratio of 0.17. FibroGen has a one year low of $24.60 and a one year high of $63.00. The company has a market capitalization of $3,984.55, a PE ratio of -27.77 and a beta of 1.89.

COPYRIGHT VIOLATION WARNING: “$28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://dakotafinancialnews.com/2018/04/14/28-23-million-in-sales-expected-for-fibrogen-fgen-this-quarter.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply